Us Congress 2023-2024 Regular Session

Us Congress Senate Bill SB1339

Introduced
4/27/23  
Refer
4/27/23  

Caption

Pharmacy Benefit Manager Reform Act

Impact

The bill aims to change the landscape of how pharmacy benefit managers interact with health plans. It introduces requirements for PBMs to report on the rebates and other financial arrangements they have with drug manufacturers, ensuring that such funds go directly to the health plans and ultimately to members. By enforcing full rebate pass-through from PBMs to health plans, the legislation seeks to lower overall prescription drug costs for patients. The bill also establishes penalties for non-compliance, thereby promoting accountability among pharmacy benefit managers.

Summary

SB1339, titled the ‘Pharmacy Benefit Manager Reform Act’, is designed to increase oversight over pharmacy benefit management (PBM) services provided on behalf of group health plans and health insurance coverage. The bill mandates that starting from January 1, 2025, any entity providing these services must allow transparency in their contracts. This means they cannot restrict the disclosure of information that is vital for plan sponsors, thus enabling better reporting and evaluation of pharmacy benefit services delivered to enrollees.

Sentiment

The sentiment surrounding SB1339 is largely positive from consumer advocacy groups and many legislators who believe that increased transparency is key to reducing prescription drug costs. Supporters argue that by holding PBMs accountable, the bill will help mitigate rising healthcare costs faced by consumers. However, some stakeholders express concern that the bill could disrupt current market practices and create unforeseen complications in drug pricing mechanisms.

Contention

Notable points of contention include the balance of power between pharmaceutical manufacturers, PBMs, and healthcare providers. While proponents assert that the reforms will protect consumers and enhance the competitive landscape, critics warn that overly stringent regulations may stifle innovation and lead to increased costs in other areas. The bill also delves into the relationship between PBMs and pharmacies, which some fear could be negatively impacted if PBMs are forced to pass through all their savings in the form of rebates.

Companion Bills

US SB652

Related Safe Step Act

US HB2630

Related Safe Step Act

US HB4005

Related Naloxone Affordability Act of 2023

US HB4712

Related Patient Right to Shop Act

Similar Bills

US HB3561

PATIENT Act of 2023 Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023

US HB4507

Transparency in Coverage Act

US HB5378

Lower Costs, More Transparency Act

US SB2254

Medicare PBM Accountability Act

US SB1374

Patient Right to Shop Act

US HB2880

Protecting Patients Against PBM Abuses Act

US HB5393

To amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes.

US SB2052

Protect Patient Access to Pharmacies Act